Acral lentiginous malignant melanoma

1		Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma	Acral Lentiginous Melanoma	Drug: pembrolizumab	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Department of Clinical Oncology, Prince of Wales Hospital Hong Kong, Hong Kong
2		A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab	Acral Lentiginous Melanoma Mucosal Melanoma	Drug: Nivolumab Drug: Ipilimumab	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Lombardi Comprehensive Cancer Center Washington, District of Columbia, United States Washington Cancer Institute at MedStar Washington Hospital Center Washington, District of Columbia, United States H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States John Theurer Cacner Center at Hackensack University Medical Center Hackensack, New Jersey, United States
3		A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread	Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma	Drug: nilotinib	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Royal Marsden NHS Foundation Trust London, United Kingdom
4		SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma	Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma	Drug: Sunitinib	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Massachusetts General Hospital Boston, Massachusetts, United States Beth Israel Deaconess Medical Center Boston, Massachusetts, United States Dana-Farber Cancer Institute Boston, Massachusetts, United States (and 2 more...)
5		Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery	Cutaneous Melanoma Mucosal Melanoma Ocular Melanoma (and 8 more...)	Biological: Ipilimumab Other: Laboratory Biomarker Analysis Biological: Nivolumab (and 2 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	M D Anderson Cancer Center Houston, Texas, United States
6		Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery	Acral Lentiginous Melanoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 (and 7 more...)	Biological: Pembrolizumab Procedure: Therapeutic Conventional Surgery	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States Anchorage Radiation Therapy Center Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States (and 506 more...)
7		Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease	Acral Lentiginous Melanoma Central Nervous System Melanoma Clinical Stage IV Cutaneous Melanoma AJCC v8 (and 6 more...)	Biological: Nivolumab	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	M D Anderson Cancer Center Houston, Texas, United States
8		Dinaciclib in Treating Patients With Stage IV Melanoma	Acral Lentiginous Melanoma Lentigo Maligna Melanoma Mucosal Melanoma (and 4 more...)	Drug: Dinaciclib	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Providence Hospital Mobile, Alabama, United States Mercy Hospital Fort Smith Fort Smith, Arkansas, United States University of Arkansas for Medical Sciences Little Rock, Arkansas, United States (and 188 more...)
9		Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	Acral Lentiginous Malignant Melanoma Recurrent Melanoma Stage IIIA Melanoma (and 3 more...)	Drug: imatinib mesylate Other: laboratory biomarker analysis	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	University of California at Los Angeles (UCLA ) Los Angeles, California, United States Mount Sinai Medical Center CCOP Miami Beach, Florida, United States Good Samaritan Medical Center West Palm Beach, Florida, United States (and 5 more...)
10		Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma	Acral Lentiginous Malignant Melanoma Lentigo Maligna Malignant Melanoma Nodular Malignant Melanoma (and 4 more...)	Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097 Other: laboratory biomarker analysis	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Providence Hospital Mobile, Alabama, United States Fairbanks Memorial Hospital Fairbanks, Alaska, United States University of Arizona Health Sciences Center Tucson, Arizona, United States (and 175 more...)
11		AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma	Acral Lentiginous Malignant Melanoma Ciliary Body and Choroid Melanoma, Medium/Large Size Ciliary Body and Choroid Melanoma, Small Size (and 8 more...)	Drug: cediranib maleate	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada
12		Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma	Melanoma	Drug: Dasatinib Procedure: Surgical Resection	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	University of Texas MD Anderson Cancer Center Houston, Texas, United States
13		Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma	Melanoma (Skin)	Biological: adenovirus RSV-TK Drug: ganciclovir	Primary Purpose: Treatment	Clinical Genetherapy Branch Bethesda, Maryland, United States Metabolism Branch Bethesda, Maryland, United States Baylor College of Medicine Houston, Texas, United States
14		Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery	Melanoma (Skin)	Drug: dasatinib Other: laboratory biomarker analysis	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States Stanford Cancer Center Stanford, California, United States Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital Fort Lauderdale, Florida, United States (and 150 more...)
15		Study of Families With Melanoma	Melanoma (Skin)	Genetic: gene expression analysis Genetic: mutation analysis Other: immunohistochemistry staining method (and 4 more...)		Leeds Cancer Centre at St. James's University Hospital Leeds, England, United Kingdom